REDWOOD CITY, Calif.,, March 6, 2014 (GLOBE NEWSWIRE) -- Informatica Corporation (Nasdaq:INFA), the world's number one independent provider of data integration software, today announced that ICON plc is improving the company's clinical trials and development process with Informatica. By standardizing on a best-in-class, multidomain Informatica MDM solution, this global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries is creating a consolidated and reliable view of business-critical data -- such as investigators and sites -- and the relationships between the data. This strategy is unleashing the potential of ICON's data: unlocking faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting. Commenting on the Informatica MDM deployment, Andrew Thompson, vice president of technology, ICON, said, "Our business is all about data. Informatica unlocks the potential of ICON's data, delivering 360-degree insights into, study and site related program activities. This enables the company to continuously monitor the clinical trials process, optimize operations based on real-time alerts and data insights and mitigate risk. The ultimate outcome is increased productivity." ICON is one of a small group of organizations with the scale, range of services and expertise to conduct clinical trials globally. Some trials have several hundred patients, some have several thousand and the trials can run for many years. Informatica MDM helps ICON realize the potential of data with a consolidated view of investigators and sites across the end-to-end clinical trials management spectrum. Now with a single view of an investigator, ICON has a much improved performance analysis capability. Improvement in future study initiation has followed so that ICON delivers greater excellence in execution. At the same time, the multidomain solution enables the company to track site enrollment and performance more effectively and highlight non-performing sites earlier. This helps ensure only high performance sites participate in clinical trials.